Cantargia reports third party appeal against EPO decision in favor of Cantargia patent
Cantargia AB today reported that a third party has filed a Notice of Appeal after their previous unsuccessful attempt to challenge the validity of one of Cantargia’s European patents. The appeal concerns the decision by the Opposition Division of the European Patent Office (EPO) to reject the opposition of Cantargia’s patent, EP 3020730, for treatment of solid tumors by IL1RAP-targeting antibody. This patent is part of Cantargia’s robust IP portfolio and as it is based on a divisional application, the parent patent is not subject of the appeal.“As Cantargia is reporting new results